NSCLC Pipeline Drugs 2025 Report by DelveInsight Highlighting Current R&D Efforts, Key Pharmaceutical Players, and the Evolution of Therapeutic Strategies

DelveInsight's "NSCLC Pipeline Insight 2025" report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the NSCLC pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the NSCLC Pipeline? Click here to explore the therapies and trials making headlines @ NSCLC Pipeline Outlook Report [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the NSCLC Pipeline Report

* On 18 September 2025, Amgen conducted a study is to characterize the safety and efficacy of 2 dose levels of AMG 193 by the investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
* On 18 September 2025, AstraZeneca announced a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable, and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
* On 17 September 2025, BlossomHill Therapeutics organized a study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and/or human epidermal growth factor receptor (HER2) mutations. The study drug, BH-30643 capsules, will be self-administered by mouth twice daily in 21-day cycles.
* On 16 September 2025, BeiGene initiated a study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surgery, or had spread to other parts of the body.
* DelveInsight's NSCLC Pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for NSCLC treatment.
* The leading NSCLC Companies such as Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience - Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech and others.
* Promising NSCLC Therapies such as Brigatinib, Tyrosine kinase inhibitor, AK104+anlotinib, Osimertinib, Gefitinib, SSGJ-707, JS111 capsules (AP-L1898), Atezolizumab, Tiragolumab, AK112, Pemetrexed, Paclitaxel and others.

Want to know which companies are leading innovation in NSCLC? Dive into the full pipeline insights @ NSCLC Clinical Trials Assessment [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The NSCLC Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The NSCLC Pipeline Report also highlights the unmet needs with respect to the NSCLC.

NSCLC Overview

Non-small cell lung cancer is the most common type of lung cancer. With this disease, cancer cells originate in your lung tissues. Non-small cell lung cancer grows slowly compared to small cell lung cancer but it often spreads to other parts of your body by the time it's diagnosed. So, early detection and non-small cell lung cancer treatment are essential.

NSCLC Emerging Drugs Profile

* V940: Merck Sharp & Dohme LLC

V940 is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient's tumor. It is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient's tumor. Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity. The drug is in Phase III stage for the treatment of NSCLC.

* QL1706: Qilu Pharmaceutical Co., Ltd.

QL1706 is an investigational bifunctional antibody with additional anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody could increase the anti-tumor effect of anti-programmed cell death 1 (PD-1) antibody. QL1706 is a novel dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA4 IgG1 antibodies produced by a single cell line. The drug is in Phase III stage for the treatment of NSCLC.

* Zenocutuzumab (MCLA-128): Merus N.V.

Zenocutuzumab (MCLA-128; Zeno) is a Biclonics antibody that overcomes HER3 mediated NRG1 (or NRG1 fusion) signaling in tumor cells. Zeno docks on HER2, then binds to and blocks the NRG1 fusion-HER3 interaction and HER3 heterodimerization with HER2. It has a dual mechanism against cancer, as it prevents NRG1 fusions from binding to the protein HER3 and it blocks the interaction of HER3 with HER2, which the cancer cells depend on to survive and multiply. Currently, the drug is in Phase II stage for the treatment of NSCLC.

* ZW49: Zymeworks BC Inc.

ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as ZW25 but armed with a cytotoxic payload. A biparatopic (targeting two different non-overlapping epitopes on ERBB2, on extracellular domains 2 (ECD2) and 4 (ECD4). ZW25 is an anti-HER2 biparatopic antibody which binds to the same domains as trastuzumab and pertuzumab. ZW25 simultaneously binds two distinct sites on HER2, a protein expressed on many types of cancer cells. This unique design results in multiple mechanisms of action, including dual HER2 signal blockade, increased antibody binding, receptor clustering, and removal of HER2 from the cell surface, and potent eector function. ZW49 is in Phase I of clinical trials for the treatment of non-small cell lung cancer.

If you're tracking ongoing NSCLC Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ NSCLC Treatment Drugs [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The NSCLC Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment.
* NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market.

NSCLC Companies

Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience - Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech and others.

NSCLC pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

NSCLC Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the NSCLC Pipeline Report covers it all - check it out now @ NSCLC Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the NSCLC Pipeline Report

* Coverage- Global
* NSCLC Companies- Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience - Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech and others.
* Promising NSCLC Therapies- Brigatinib, Tyrosine kinase inhibitor, AK104+anlotinib, Osimertinib, Gefitinib, SSGJ-707, JS111 capsules (AP-L1898), Atezolizumab, Tiragolumab, AK112, Pemetrexed, Paclitaxel and others.
* NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the NSCLC Treatment landscape in this detailed analysis @ NSCLC Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Non-Small-Cell Lung cancer (NSCLC): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Non-Small-Cell Lung cancer (NSCLC) - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* V940: Merck Sharp & Dohme LLC
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Zenocutuzumab (MCLA-128): Merus N.V.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ZW49: Zymeworks BC Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Non-Small-Cell Lung cancer (NSCLC) Key Companies
* Non-Small-Cell Lung cancer (NSCLC) Key Products
* Non-Small-Cell Lung cancer (NSCLC) - Unmet Needs
* Non-Small-Cell Lung cancer (NSCLC) - Market Drivers and Barriers
* Non-Small-Cell Lung cancer (NSCLC) - Future Perspectives and Conclusion
* Non-Small-Cell Lung cancer (NSCLC) Analyst Views
* Non-Small-Cell Lung cancer (NSCLC) Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nsclc-pipeline-drugs-2025-report-by-delveinsight-highlighting-current-rd-efforts-key-pharmaceutical-players-and-the-evolution-of-therapeutic-strategies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.